Stocks / Biotech

EXELBiotech

Exelixis Inc
$56.261d +0.2%5d -4.7%settled close · 2026-09-14
Mkt cap $11B (3/25)β 0.6452w $35–59Shares 259.7MInd. Biological Products, (No Diagnostic Substances)Nasdaq since 2000Emp. 1,077HQ Alameda, CAexelixis.com
Who’s talkingIdea Scout · free

Who’s talking about EXEL

No tracked investor commentary on EXEL yet — the corpus grows weekly.
Idea Scout tracks who’s talking across television, podcasts, and interviews — every stance dated to the appearance it came from. Sign up free →
Earnings

Next report: 2 Nov 2026

Confirmed date · consensus EPS 0.84. Reactions below are the next settled session over the prior close.
The options tape

Notable options days

Sessions in the last 120 where EXEL’s settled options volume ran ≥ 2× its trailing 20-session baseline, or delta-dollar flow ran ≥ 2.5× — 23 of 120 sessions qualified.

The qualifying dates are the free record. Close, flow, call/LEAPS mix and the 20-session outcome — for every session below — are Brief subscriber content.
DateCloseRVOL Δ$ flow ($M)Call % LEAPS %+20 sess.
2026-09-11
2026-09-01
2026-08-27
2026-08-10
2026-08-05
2026-08-03
2026-07-17
2026-07-07
2026-07-02
2026-06-24
2026-06-18
2026-05-14
2026-05-13
2026-05-12
2026-05-11
2026-05-07
2026-05-06
2026-05-05
2026-04-24
2026-04-23
2026-04-22
2026-04-21
2026-04-20
+20 sess. = raw price change over the following 20 sessions — not market-adjusted; the tape tells you where to look, not what happens next.
Today’s tape on EXEL is in this morning’s Brief. Get The Brief — $20/mo →